Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: Follow-up from months 12–24 in a Phase III randomized study of healthy women aged 18–45 years

In this observer-blind study (NCT00423046), women (N = 1,106), stratified by age (18–26, 27–35, 36–45 y), were randomized (1:1) to receive the HPV-16/18 vaccine (Cervarix(®), GlaxoSmithKline Biologicals, Months 0, 1, 6) or the HPV-6/11/16/18 vaccine (Gardasil(®) Merck and Co., Inc., Months 0, 2, 6)....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Einstein, Mark H, Baron, Mira, Levin, Myron J, Chatterjee, Archana, Fox, Bradley, Scholar, Sofia, Rosen, Jeffrey, Chakhtoura, Nahida, Meric, Dorothée, Dessy, Francis J, Datta, Sanjoy K, Descamps, Dominique, Dubin, Gary
Formato: Artigo
Idioma:Inglês
Publicado em: Landes Bioscience 2011
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3338932/
https://ncbi.nlm.nih.gov/pubmed/22048173
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/hv.7.12.18281
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados